Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Mere på finanzen.net
SynBiotic share plunges almost 20% after US cannabis reclassification

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Mere på finanzen.net
Synbiotic shares more than double since Friday after anchor investor steps in

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har SynBiotic allerede udloddet 0,30 € i udbytte. Den seneste udlodning fandt sted i juli 2022.

Virksomhedstal

I det seneste år havde SynBiotic en omsætning på 3,86 mio. € og et nettoresultat på -10,63 mio. €

(EUR)	2023	YoY
Omsætning	3,86 mio.	52,71 %
Bruttofortjeneste	1,51 mio.	57,83 %
Nettoresultat	-10,63 mio.	56,36 %
EBITDA	-7,12 mio.	4,85 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	4,84 mio. €
Antal aktier	4,75 mio.
Højeste/laveste i 52 uger	3,85 € - 0,50 €
Udbytte	Nej
Beta	0,68
P/E (PE Ratio)	-0,45
PEG (PEG Ratio)	0,00
K/I (PB Ratio)	0,31
P/S (PS Ratio)	1,25

Virksomhedsprofil

SynBiotic SE beschäftigt sich mit der Entwicklung von Medikamenten und rezeptfreien Wellness-Produkten auf der Basis von Cannabinoiden. Das Unternehmen konzentriert sich auf die synthetische Herstellung von Cannabinoiden, die Entwicklung von Medikamenten, Nahrungsergänzungsmitteln und kosmetischen Produkten. Das Unternehmen war früher als Ledgertech SE bekannt und änderte seinen Namen in Ledgertech SE. SynBiotic SE hat seinen Sitz in München, Deutschland.

Navn	SynBiotic
CEO	Daniel Kruse
Hjemsted	Düsseldorf, nw Tyskland
Websted	synbiotic.com/de
Sektor	Sundhed
Branche	Bioteknologi
Børsnotering	07.01.2021
Medarbejdere	79